Business
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS Top Line Results for CLEAR MIND Alzheimer’s disease Phase 2a Trial
About this update from Longeveron Inc.
[{"type":"text","content":"ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS Top Line Results for CLEAR MIND Alzheimer’s disease Phase 2a Trial Anticipated by October 2023 Company Strengthens Leadership Team and Board of Directors with Distinguished New Additions Company to Hold Conference Call and Webcast Today, August 11, 2023 at 8am Eastern Time MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (\"Longeveron\" or \"Company\"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended June 30, 2023 and provided a corporate update. “During our second quarter and in recent weeks, we made significant progress advancing our Lomecel-B™ clinical programs, exceeding the 50% enrollment threshold for our ELPIS II trial in hypoplastic left heart syndrome (HLHS) patients and announcing new long-term survival data from our ELPIS I study,” said Wa’el Hashad, Chief Executive Officer of Longeveron. “HLHS patients are in critical need of new therapeutic options to improve outcomes in this rare and life-threatening indication, and we look forward to completing enrollment in the ELPIS II trial by mid-2024. Additionally, we are on track and expect to report top-line results from our CLEAR MIND Phase 2a trial of Lomecel-B™ treatment of Alzheimer’s disease by October 2023, and we continue to enroll patients in Phase 2 of Lomecel-B™ in patients with Aging-related Frailty at centers in Japan. Finally, we are pleased to welcome distinguished new colleagues to both our leadership team and Board of Directors. We look forward to their guidance and counsel as we advance Lomecel-B™ in areas of significant unmet medical needs.” Recent Highlights Lomecel-B™ for Hypoplastic Left Heart Syndrome (HLHS): Announced achievement of exceeding 50% enrollment threshold for Phase 2 ELPIS II trial of Lomecel-B™ in HLHS.Announced new long-term survival data from ELPIS I Trial of Lomecel-B™ for HLHS. Children in the ELPIS I trial had 100% survival up to five years of age after receiving Lomecel-B™ compared to approximate 20% mortality rate observed from historical control data.Data reinforce potential survival benefit of Lomecel-B™ for patients in this indication. Lomecel-B™ for Alzheimer’s Disease: In November 2022, Longeveron announced it had compl...